Nuance Pharma Signs a License and Supply Agreement with Bavarian Nordic to Develop and Commercialize of Respiratory Syncytial Virus Vaccine
Shots:
- Bavarian Nordic to receive $12.5M up front & is eligible to receive additional fees of ~$212.5M upon achievement of clinical, regulatory & commercial milestones along with royalties
- Nuance gets the rights to commercialize MVA-BN RSV in Chinese Mainland, Hong Kong, Macau, Taiwan, South Korea & Southeast Asia and will be responsible for all costs including clinical development & regulatory filings. Bavarian Nordic will manufacture & supply doses post launch
- Bavarian Nordic is expected to initiate a P-III trial of MVA-BN RSV in the USA & Germany in H1’22. MVA-BN RSV has received BTD from the US FDA for lower respiratory tract disease caused by RSV in adults aged ≥60yrs.
Ref: Nuance Pharma | Image: PR Newswire
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
